Immunocore (IMCR) Projected to Post Earnings on Wednesday

Immunocore (NASDAQ:IMCR) is anticipated to release its Q4 2025 results before the market opens on Wednesday, February 25th. Analysts expect Immunocore to post earnings of ($0.28) per share for the quarter. Interested persons can check the company’s upcoming Q4 2025 earning summary page for the latest details on the call scheduled for Wednesday, February 25, 2026 at 8:00 AM ET.

Immunocore Stock Up 0.8%

IMCR stock opened at $32.93 on Tuesday. Immunocore has a twelve month low of $23.15 and a twelve month high of $40.71. The firm has a market capitalization of $1.66 billion, a PE ratio of -57.77 and a beta of 0.78. The company has a quick ratio of 5.97, a current ratio of 6.00 and a debt-to-equity ratio of 0.99. The stock has a 50-day simple moving average of $33.75 and a two-hundred day simple moving average of $34.33.

Insider Buying and Selling

In other Immunocore news, insider Leger Tina Amber St sold 1,000 shares of Immunocore stock in a transaction dated Wednesday, February 18th. The stock was sold at an average price of $32.35, for a total transaction of $32,350.00. Following the completion of the sale, the insider owned 1,119 shares of the company’s stock, valued at $36,199.65. The trade was a 47.19% decrease in their ownership of the stock. The sale was disclosed in a document filed with the SEC, which is available at this hyperlink. Also, CEO Bahija Jallal sold 11,474 shares of the company’s stock in a transaction dated Wednesday, February 18th. The stock was sold at an average price of $32.35, for a total value of $371,183.90. Following the completion of the transaction, the chief executive officer owned 12,343 shares of the company’s stock, valued at $399,296.05. The trade was a 48.18% decrease in their ownership of the stock. The SEC filing for this sale provides additional information. Over the last ninety days, insiders sold 19,137 shares of company stock worth $619,082. Corporate insiders own 10.40% of the company’s stock.

Institutional Trading of Immunocore

A number of hedge funds have recently bought and sold shares of the company. Royal Bank of Canada boosted its stake in Immunocore by 45.1% in the first quarter. Royal Bank of Canada now owns 44,011 shares of the company’s stock worth $1,306,000 after buying an additional 13,689 shares in the last quarter. Geode Capital Management LLC lifted its holdings in shares of Immunocore by 40.1% in the 2nd quarter. Geode Capital Management LLC now owns 52,001 shares of the company’s stock worth $1,632,000 after acquiring an additional 14,877 shares during the last quarter. Marshall Wace LLP boosted its stake in shares of Immunocore by 425.8% in the 2nd quarter. Marshall Wace LLP now owns 146,610 shares of the company’s stock valued at $4,601,000 after purchasing an additional 118,728 shares in the last quarter. Sei Investments Co. bought a new position in shares of Immunocore during the 2nd quarter valued at $983,000. Finally, Cubist Systematic Strategies LLC raised its position in Immunocore by 108.0% in the 2nd quarter. Cubist Systematic Strategies LLC now owns 142,757 shares of the company’s stock worth $4,480,000 after purchasing an additional 74,128 shares during the period. Institutional investors own 84.50% of the company’s stock.

Analysts Set New Price Targets

A number of analysts recently weighed in on the stock. Zacks Research raised shares of Immunocore from a “hold” rating to a “strong-buy” rating in a report on Wednesday, January 7th. Morgan Stanley boosted their price target on shares of Immunocore from $34.00 to $36.00 and gave the company an “equal weight” rating in a research report on Monday, November 10th. HC Wainwright reaffirmed a “buy” rating and issued a $100.00 price target on shares of Immunocore in a report on Wednesday, February 4th. Wells Fargo & Company assumed coverage on Immunocore in a research report on Friday, October 31st. They issued an “overweight” rating and a $60.00 price objective on the stock. Finally, Wall Street Zen lowered Immunocore from a “buy” rating to a “hold” rating in a research note on Saturday, January 31st. One analyst has rated the stock with a Strong Buy rating, eight have assigned a Buy rating, three have given a Hold rating and one has given a Sell rating to the company. Based on data from MarketBeat, the company currently has an average rating of “Moderate Buy” and an average price target of $60.90.

Immunocore Company Profile

Immunocore plc is a clinical‐stage biotechnology company focused on the development of novel immunotherapies that harness the body’s own T‐cell response to treat cancer and infectious diseases. The company’s proprietary ImmTAC (immune mobilising monoclonal T‐cell receptors against cancer) platform utilizes engineered, soluble T‐cell receptor (TCR) molecules designed to recognise intracellular peptide–HLA complexes. By redirecting and activating T cells against disease‐associated targets, Immunocore aims to address malignancies and persistent viral infections with high unmet medical need.

The company’s most advanced candidate, tebentafusp, is a bispecific ImmTAC molecule that targets gp100, a melanoma‐associated antigen, and has received regulatory approval for the treatment of metastatic uveal melanoma.